Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Prepares To Launch Canada's First Trastuzumab Within Weeks

Executive Summary

By the end of June, Mylan expects to have launched in Canada the Ogivri trastuzumab 150mg and 440mg vials for which it has just received regulatory approval.

You may also be interested in...

Mylan And Biocon Launch Fulphila In Canada

Mylan and Biocon have introduced the second biosimilar pegfilgrastim rival to Neulasta in Canada with the launch of their Fulphila version.

Celltrion And Teva Catch Up On Canadian Trastuzumab

Celltrion and Teva have now received a Health Canada approval for their Herzuma trastuzumab biosimilar. However, notices of compliance have already been granted for rival biosimilars from Mylan and Pfizer.

Biocon Expects ‘Successful’ US Trastuzumab Launch Despite Amgen Debut

India’s Biocon reported first-quarter net profit that soared by more than 70% and said it was confident of a “very successful” US trastuzumab launch, despite rival Amgen stealing a march by commercializing its own biosimilar first in the world’s largest drug market.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts